nontuberculous%20mycobacterial%20disease
NONTUBERCULOUS MYCOBACTERIAL DISEASE
Nontuberculous mycobacteria are ubiquitous and are usually found in soil, natural and treated water sources. They are relatively uncommon cause of pulmonary disease and likely to cause disseminated disease.
May cause both asymptomatic infection and symptomatic disease in humans.
There is no evidence of animal-to-human or human-to-human transmission in immunocompetent hosts.
Nontuberculous mycobacterial pulmonary disease is a generally slowly progressive infection.
Signs and symptoms are generally nonspecific.
Drug Information

Indication: Infections of nose-pharynx tract (tonsillitis, pharyngitis) & of paranasal sinuses; lower resp tract: bron...

Indication: Infections caused by susceptible organisms in lower resp tract (eg, bronchitis, pneumonia), skin & soft ti...

Indication: Tab/powd for oral susp Lower resp tract infections including bronchitis & pneumonia; skin & soft tissu...

Indication: Polymicrobic & mixed aerobic/anaerobic infections. Initial therapy prior to the identification of the caus...

Indication: Bacterial infections caused by susceptible strains: Community-acquired pneumonia, complicated skin & skin ...

Indication: Upper resp tract infection including sinusitis, pharyngitis, tonsillitis; acute otitis media, lower resp tract...

Indication: Lower resp tract infections eg, bronchitis & pneumonia, odontostomatological, skin & soft tissue infec...

Indication: Purulent bacterial & trachomatous conjunctivitis caused by Chlamydia trachomatis in adults & childn fr...

Indication: Lower resp tract infections including bronchitis & pneumonia; skin & soft tissue infections; otitis me...

Indication: Nasopharyngeal, lower resp tract, skin & soft tissue infections.

1  /  5
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 25 Jun 2019

Due to the apparent risk of adverse outcomes of disease and adverse events (AEs) associated with short-acting beta-agonists (SABA), the Global Initiative for Asthma (GINA) 2019 guideline recommends that all patients with mild asthma should receive symptom-driven or regular low-dose inhaled corticosteroid (ICS)containing controller treatment.